Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy

Evaluation of Quantitative Relationship Between Target Expression and ADC Exposure Inside Cancer Cells

(2020) Sharad Sharma et al.   DRUG METABOLISM AND DISPOSITION

Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade

(2020) Liangliang Wang et al.   Science Translational Medicine

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

(2019) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Antibody–drug conjugates for cancer

(2019) Cindy H Chau et al.   LANCET

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

(2019) Yilun Wu et al.   Frontiers in Immunology

The function and dysfunction of memory CD8+ T cells in tumor immunity

(2018) James L. Reading et al.   IMMUNOLOGICAL REVIEWS

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Avelumab: A Review in Metastatic Merkel Cell Carcinoma

(2018) Matt Shirley   Targeted Oncology

Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia

(2018) Jeffrey Baron et al.   Expert Review of Clinical Pharmacology

Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

(2018) Meghdad Abdollahpour-Alitappeh et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Tim-3 and its role in regulating anti-tumor immunity

(2017) Madhumita Das et al.   IMMUNOLOGICAL REVIEWS

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

(2017) Andrea B. Apolo et al.   JOURNAL OF CLINICAL ONCOLOGY

TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement

(2017) Joong-Hyuk Sheen et al.   JOURNAL OF IMMUNOLOGY

Linkers Having a Crucial Role in Antibody–Drug Conjugates

(2016) Jun Lu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor

(2016) Rong Deng et al.   mAbs

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates

(2016) Leanna R. Staben et al.   Nature Chemistry

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

(2016) Kyoji Tsuchikama et al.   Protein & Cell

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

(2015) Jessica R. McCombs et al.   AAPS Journal

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

(2015) Maria Corinna A Palanca-Wessels et al.   LANCET ONCOLOGY

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

(2015) Boris Shor et al.   MOLECULAR IMMUNOLOGY

Immune modulation for cancer therapy

(2014) J Naidoo et al.   BRITISH JOURNAL OF CANCER

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Tumor Immunotherapy Directed at PD-1

(2012) Antoni Ribas   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

The Human Papillomavirus Type 16 E5 Oncoprotein Inhibits Epidermal Growth Factor Trafficking Independently of Endosome Acidification

(2010) Frank A. Suprynowicz et al.   JOURNAL OF VIROLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs

(2008) Jagath R. Junutula et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY